Research-Grade Peptides | 99%+ Purity Verified | US Delivery 2–5 Days
Save 5% with Crypto
SaiyanMed

Your Cart

No products in the cart.

What Is Eloralintide + Retatrutide Blend? Research Combination Overview

By SaiyanMed Research Team · Updated 9 November 2026 · For in-vitro research use only

RESEARCH USE ONLY — PROFESSIONAL LABORATORY USE. This article is for qualified laboratory personnel carrying out in-vitro assays or institutionally approved laboratory animal studies. It is not a home-use, personal-use, human-use, or veterinary-use guide. The information below must not be used as an administration, formulation, reconstitution, or dosing plan. Eloralintide and retatrutide are investigational peptides. Discussing them together as a research combination topic does not mean a co-formulated product is approved, that combination safety/efficacy is established, or that SaiyanMed lists a combination SKU. Clinical and preclinical results cited for each parent molecule are published research data, not medical advice. Component RUO references are linked separately.


Quick answer

Eloralintide + retatrutide blend is the name research-supply and peptide-research communities most often use for pairing two distinct investigational Lilly peptides:

  • Eloralintide (LY3841136) — a selective, long-acting amylin receptor agonist (AMY1R-preferring framing in public materials).
  • Retatrutide (LY3437943) — a unimolecular GIP / GLP-1 / glucagon triple agonist.

In this niche, multi-peptide research pairings are commonly labeled a blend (also written Elo+Reta blend, eloralintide retatrutide blend). That is a descriptive community name, not a verified Lilly brand and not the same product as EloraTZP.

Researchers discuss the pair because the pathways are mechanistically complementary on paper: amylin-pathway satiety biology on one side, and multi-incretin / glucagon receptor pharmacology on the other. That is a hypothesis / literature-mapping rationale, not a claim that the blend has been validated as a single approved product.

Critical disambiguation (read this first):
This page is not about EloraTZP. EloraTZP is Lilly’s investigational combination of eloralintide + tirzepatide (dual GIP/GLP-1). An eloralintide + retatrutide blend replaces tirzepatide’s dual-agonist arm with retatrutide’s triple-agonist arm (adds glucagon-receptor agonism). Mixing up the two names will scramble search intent and literature maps.

For a side-by-side monotherapy comparison (not combination framing), see Eloralintide vs Retatrutide.

Why researchers talk about this pairing

Obesity and metabolic research has moved from single-pathway incretin tools toward multi-pathway designs: dual agonists, triple agonists, and amylin + incretin combinations (sponsor examples include EloraTZP and, from another sponsor lineage, CagriSema). Against that backdrop, eloralintide + retatrutide shows up in research discussions for three literacy reasons:

  1. Different receptor families. Eloralintide is framed around amylin signaling; retatrutide is framed around GIP, GLP-1, and glucagon receptors. The pair is not “two GLP-1s.”
  2. Separate mature evidence maps. Each parent molecule already has public clinical-development history as a monotherapy (see sections below). That makes the components easy to document even when the pair lacks a dedicated combo readout.
  3. Architecture contrast with named combos. Lilly’s public amylin+incretin combination branding in 2026 centers on EloraTZP (eloralintide + tirzepatide). Discussing eloralintide + retatrutide is therefore a way to teach “amylin + which incretin architecture?” without treating every informal shorthand as a sponsor brand.

None of those points invents a co-formulation code, a Phase 2/3 combo table, or a dosing schedule for the pair.

Components: eloralintide + retatrutide blend

Eloralintide (amylin pathway)

Eloralintide is Lilly’s investigational once-weekly selective amylin receptor agonist, previously known as LY3841136. Public sponsor materials describe potential effects on calorie intake via satiety biology and emphasize selectivity themes (including limited calcitonin-receptor activity in EloraTZP-related framing).

Public monotherapy evidence landmarks (not combo data):
– Phase 2 obesity study NCT06230523 (48 weeks; adults with obesity/overweight without type 2 diabetes) with results presented around ObesityWeek 2025 and published in The Lancet.
– Lilly IR summary of efficacy-estimand mean weight change across arms approximately −9.5% to −20.1% vs −0.4% placebo at 48 weeks (monotherapy trial; cite sponsor/Lancet, not as Elo+Reta results).
– Mono Phase 3 direction under ENLIGHTEN-class programs (see live What Is Eloralintide? for identity depth).

Deep reading: What Is Eloralintide? · Eloralintide RUO product (component reference material — not a combination vial).

Retatrutide (GIP + GLP-1 + glucagon pathway)

Retatrutide is Lilly’s investigational once-weekly triple hormone receptor agonist (LY3437943) that activates receptors for GIP, GLP-1, and glucagon in a single molecule.

Public monotherapy evidence landmarks (not combo data):
– Phase 2 obesity literature (including NEJM reporting of large mean weight reductions at 48 weeks in a separate monotherapy program — use only as mono context).
– Phase 3 TRIUMPH program with multiple public readouts; Lilly IR (2026-07-23) summarized TRIUMPH-2 / TRIUMPH-3 toplines and noted a planned U.S. BLA timing discussion for retatrutide as a monotherapy asset.
– Registry anchors commonly cited on SaiyanMed’s retatrutide hub include TRIUMPH-2 (NCT05929079) and TRIUMPH-3 (NCT05882045).

Deep reading: What Is Retatrutide? · Retatrutide RUO product (component reference material — not a combination vial) · receptor deep-dive: Retatrutide receptor pharmacology.

How this blend is labeled

Label you may see What it usually means Use on SaiyanMed?
Eloralintide + retatrutide blend / Elo + Reta blend Community name for this two-peptide pairing Preferred educational title on this hub
Eloralintide + retatrutide / Elo + Reta Same pairing without the blend suffix Also used; this page treats it as the same topic
Informal shorthand (“EloReta,” “EloraReta,” etc.) Community nickname, not a verified sponsor brand Mention only as informal shorthand; do not treat as official product name
EloraTZP Eloralintide + tirzepatide (Lilly combination program) Different page — What Is EloraTZP?
LY3841136 + LY3437943 Development codes for the two parent molecules Good identity anchors
Unverified ratio / “recipe” stickers on a vial Supplier marketing, not clinical identity or a COA Not used as evidence or a protocol

Mechanistic context (why the pathways are discussed together)

Amylin arm (eloralintide)

Amylin is a pancreatic peptide historically linked to satiety / meal-size biology and complementary nutrient-stimulated hormone signaling. Selective amylin agonists are studied as a non-incretin lever relative to pure GLP-1 tools. Eloralintide’s public story is “amylin receptor selectivity + weekly peptide pharmacokinetics,” not “another GLP-1.”

Triple-agonist arm (retatrutide)

Retatrutide’s public story is breadth within one molecule: GIP and GLP-1 receptor agonism plus glucagon receptor agonism. That architecture is different from tirzepatide (GIP+GLP-1 dual) and different from amylin monotherapy.

Pairing rationale (hypothesis level only)

Putting the two on the same research whiteboard usually means:

  • Pathway complementarity: amylin signaling + multi-incretin/glucagon signaling.
  • Contrast to EloraTZP: same amylin component family discussion, but the incretin partner is a triple agonist rather than tirzepatide.
  • Contrast to CagriSema: CagriSema is a different sponsor’s amylin analog (cagrilintide) + semaglutide (GLP-1) combination program — useful as class literacy, not as a synonym (What Is CagriSema?).

This section is mechanistic literacy, not proof that co-administration multiplies monotherapy percentages.

What is known vs what is not known about combination use

Known (documentable today)

  • Chemical / programmatic identity of each parent molecule (INN + LY codes).
  • Separate public clinical programs and publications for eloralintide monotherapy and retatrutide monotherapy.
  • A named Lilly combination program that pairs eloralintide with tirzepatide (EloraTZP), including public Phase 2b communication and Phase 3 co-formulation direction — useful as the closest documented “amylin + incretin” Lilly combo template, not as Elo+Reta data.
  • Research-community attention to Elo+Reta as a pairing topic (search/forum literacy), which is why an educational hub helps disambiguate Google intent from EloraTZP.

Not known / not claimed on this page

  • No SaiyanMed claim of an official Lilly brand exclusively meaning “eloralintide + retatrutide co-formulation.”
  • No Elo+Reta combination efficacy table is presented here, because this hub does not invent one.
  • No dosing, titration, reconstitution, injection schedule, or “stack protocol.”
  • No assertion that community anecdotes equal clinical evidence.
  • No FDA (or other regulator) approval of either molecule as a combination product for human use.

Research stance: map the components, keep the architecture honest, and update this hub if/when a dedicated sponsor combo program or peer-reviewed co-administration study becomes public.

How this differs from EloraTZP

Dimension Eloralintide + retatrutide (this page) EloraTZP
Components Eloralintide + retatrutide Eloralintide + tirzepatide
Incretin architecture Triple agonist (GIP/GLP-1/glucagon) partner Dual agonist (GIP/GLP-1) partner
Glucagon receptor arm Present in the retatrutide component (as a unimolecular triple agonist) Not the tirzepatide dual-agonist design
Public Lilly combo branding Descriptive research pairing Named combination communications (EloraTZP / related Phase 3 co-formulation direction)
SaiyanMed hub This article What Is EloraTZP?

If your question is “Lilly’s amylin + tirzepatide combination,” go to EloraTZP. If your question is “amylin analog + retatrutide triple agonist discussed together,” stay here.

How this differs from each monotherapy (and from the vs page)

  • Eloralintide alone: amylin-pathway asset; see mono hub and ENLIGHTEN/Ph2 map.
  • Retatrutide alone: triple-agonist asset; see TRIUMPH/TRANSCEND map on the retatrutide hub.
  • Eloralintide vs retatrutide: compares the two as separate tools (receptors, codes, why cross-trial % is not a ranking) — comparison page.
  • This combination hub: discusses why people map them together, and what evidence boundaries still apply.

Architecture contrast vs other multi-pathway programs (class literacy)

Use these only as class maps, not rankings:

  • EloraTZP — eloralintide + tirzepatide (hub).
  • CagriSema — cagrilintide + semaglutide, different sponsor lineage (hub).
  • Survodutide — dual GLP-1/glucagon agonist (BI/Zealand lineage) (hub).
  • MariTide — antibody/peptide metabolic program literacy (hub).
  • Retatrutide monotherapy — unimolecular triple agonist without a separate amylin co-agent (hub).

Research / analytical identity notes

Why a blend name is not the same as clinical identity

Calling this pairing an eloralintide + retatrutide blend matches how the research community names multi-peptide combinations. That label still is not a Certificate of Analysis and not a clinical protocol. Ratio stickers or unverified “recipes” on a vial are supplier text, not identity proof. For laboratory purchasing of components, identity still collapses to lot-level analytics for each peptide.

Component vs combination

SaiyanMed’s educational position on this hub:

  • Document eloralintide and retatrutide as separate research materials when listed.
  • Do not treat this article as a combination catalog SKU.
  • Do not infer that any listed mono vial is a co-formulation.

Handling themes (no recipes)

Laboratory handling belongs in SOPs: identity confirmation, storage conditions per COA, contamination control, and institutional compliance. This page provides no reconstitution volumes, solvents, concentrations, or administration schedules.

Stock status on SaiyanMed

No eloralintide + retatrutide blend catalog SKU is claimed on this page. Educational hub only. Related mono RUO references:

Contact research support for notify-if-stock only after explicit go-ahead and COA review — do not assume combo inventory from this article.

Minimum COA packet (if evaluating component lots)

For each parent peptide lot under consideration as RUO material, a serious packet typically includes: stated identity (INN/code), purity method, net peptide content / fill accountability, appearance, and lot/date fields that match the physical vial. Combo marketing language does not replace per-analyte COA discipline.

Myth vs evidence

Myth Evidence-based correction
“Eloralintide + retatrutide is the same as EloraTZP.” EloraTZP is eloralintide + tirzepatide. This pairing uses retatrutide.
“Elo+Reta is just another name for retatrutide.” Retatrutide is a triple agonist monotherapy asset; eloralintide is a separate amylin agonist.
“Blend means this is an official Lilly co-formulation.” Blend is the community name for the pairing. It is not treated here as a verified sponsor brand.
“Monotherapy % numbers can be added to predict the combo.” Cross-program arithmetic is not a combination trial.
“Forum stack stories are Phase 2 evidence.” Anecdotes are not controlled clinical results.
“This SaiyanMed hub sells the blend.” Educational page only; no blend SKU claimed here.

Glossary

  • Eloralintide (LY3841136): Investigational selective long-acting amylin receptor agonist.
  • Retatrutide (LY3437943): Investigational GIP/GLP-1/glucagon triple agonist.
  • EloraTZP: Lilly investigational combination of eloralintide + tirzepatide (different from this page).
  • Amylin pathway: Satiety-linked receptor biology distinct from classical incretin dual/triple agonist designs.
  • Triple agonist: Single molecule engaging three receptor targets (here: GIP, GLP-1, glucagon).
  • RUO: Research Use Only — not for human or veterinary administration.
  • COA: Certificate of Analysis for a specific lot.
  • ENLIGHTEN: Public mono-eloralintide Phase 3 program naming family (see Elo hub).
  • TRIUMPH: Public retatrutide Phase 3 program naming family (see Reta hub).

FAQ

What is an eloralintide + retatrutide blend?

It is the common research-community name for pairing two investigational peptides: the amylin receptor agonist eloralintide (LY3841136) and the triple agonist retatrutide (LY3437943). “Blend” here is a descriptive label used for this kind of multi-peptide research combination — not a Lilly brand name. This hub explains identity, pathway rationale, and evidence limits.

Is this the same as EloraTZP?

No. EloraTZP is eloralintide + tirzepatide. See What Is EloraTZP?.

Is “blend” an official brand name for eloralintide + retatrutide?

No. This page uses eloralintide + retatrutide blend because that is how research communities typically name this kind of pairing. It is a descriptive label, not a verified Lilly product brand. Informal shorthand (EloReta, EloraReta) may appear online; those are not treated here as official names.

Has a dedicated combination trial for eloralintide + retatrutide been summarized on this page?

This educational hub does not present a dedicated Elo+Reta combination efficacy dataset. It maps parent-molecule programs and explains why the pairing is discussed. Update this section if a public sponsor combo program appears.

What are LY3841136 and LY3437943?

Development codes commonly associated with eloralintide and retatrutide, respectively.

How does this differ from CagriSema?

CagriSema pairs cagrilintide + semaglutide under a different sponsor development lineage. It is an amylin+GLP-1 class comparator, not the same components (What Is CagriSema?).

How does this differ from retatrutide alone?

Retatrutide alone is a unimolecular triple agonist. This page discusses interest in adding an amylin-pathway agent (eloralintide) conceptually alongside that architecture — without turning the concept into a protocol.

Are eloralintide or retatrutide FDA-approved?

As investigational research topics on SaiyanMed, treat them as not approved for the uses discussed on consumer/medical blogs. Always verify current regulatory status from primary regulators/sponsors; this page is not an approval tracker.

Does SaiyanMed sell an eloralintide + retatrutide blend SKU?

No blend SKU is claimed on this page. For mono RUO reference material see eloralintide and retatrutide. This hub is research education only.

Can I use monotherapy trial percentages as a personal protocol or stack recipe?

No. Trial figures are published research data under specific protocols. This page provides no dosing, reconstitution, titration, or co-administration guidance.

Key takeaways

  • Eloralintide + retatrutide blend = the common community name for an educational research pairing of an amylin agonist and a GIP/GLP-1/glucagon triple agonist.
  • Not EloraTZP (that is eloralintide + tirzepatide).
  • Parent molecules each have public monotherapy development stories; this hub does not invent a combo efficacy table.
  • SaiyanMed page = RUO education, no combination SKU, no dosing.
  • Use mono hubs + the vs page for deeper single-agent and comparison literacy.

Related reading & research inquiry

For institutional RUO sourcing questions (COA review, component availability), use SaiyanMed research contact channels — not this article’s comments as a protocol desk.

Research Use Only disclaimer

All SaiyanMed educational content on investigational peptides is for professional laboratory research contexts. Nothing here authorizes human consumption, clinical treatment, veterinary use, or compounding instructions. Laws and platform rules vary; buyers and institutions are responsible for lawful RUO use. When in doubt, stop and verify with primary literature, institutional compliance, and legal counsel.

Sources & further reading

  1. Lilly IR — eloralintide Phase 2 monotherapy announcement / ObesityWeek–linked communication: https://investor.lilly.com/news-releases/news-release-details/lillys-selective-amylin-agonist-eloralintide-demonstrated
  2. The Lancet — eloralintide Phase 2 publication (NCT06230523): https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02155-5/abstract
  3. ClinicalTrials.gov — NCT06230523 (eloralintide Phase 2 mono)
  4. Lilly IR — EloraTZP (eloralintide + tirzepatide) EASD/Phase 2b communication: https://investor.lilly.com/news-releases/news-release-details/lillys-eloratzp-combination-eloralintide-and-tirzepatide
  5. ClinicalTrials.gov — NCT06603571 (eloralintide ± tirzepatide Ph2b context); NCT07881432 (AMPLIFY / EloraTZP Phase 3 direction)
  6. Lilly IR — retatrutide TRIUMPH Phase 3 toplines (2026-07-23): https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
  7. ClinicalTrials.gov — TRIUMPH program examples NCT05929079, NCT05882045
  8. Retatrutide Phase 2 monotherapy literature: Jastreboff AM et al., N Engl J Med (2023) — cite for mono triple-agonist context only
  9. SaiyanMed live hubs used for structure/disambiguation: https://saiyanmed.com/what-is-eloratzp/ · https://saiyanmed.com/what-is-eloralintide/ · https://saiyanmed.com/what-is-retatrutide/ · https://saiyanmed.com/eloralintide-vs-retatrutide/